222

PLUMBLINE LIFE SCIENCES

No trades
See on Supercharts

222670 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Plumbline Life Sciences, Inc. engages in the manufacturing of drugs for animals. It develops deoxyribonucleic acid (DNA)-based vaccines and therapies for animals using plasmid-based DNA delivery and expression technology by electroporation to optimize an animal's natural biological and immunological potential. The company's solutions include growth hormone releasing hormone (GHRH), a naturally occurring molecule; and an electroporation technology for delivering plasmids into skeletal muscle cells and skin. Its products are used for dog cancer/anemia, equine laminitis, cat renal failure/anemia, dog renal failure/anemia, and swine GHRH. The company was founded on January 2, 2014 and is headquartered at Seoul, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

222670 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company